Technical Articles
PCSK9-LDLR
Research Advances in PCSK9 Inhibitors Based on TR-FRET Technology for the Prevention and Treatment of Ischemic Stroke
PCSK9 is primarily synthesized and secreted by the liver as a serine protease, playing a crucial role in maintaining cholesterol homeostasis. PCSK9 elevates LDL-C levels by inhibiting circulating LDLR, competitively binding to LDLR on the surface of hepatocytes to form a PCSK9/LDLR complex. This complex is then transported into the cell via vesicles and degraded by lysosomes, leading to increased plasma LDL-C levels.
View details
- Neuroscience
- TR-FRET Technology
- PCSK9-LDLR
- Ischemic Stroke
- 1













